Results 201 to 210 of about 1,804,103 (360)

Tumor Promoter-Stimulated Protein Phosphorylation in Mouse Epidermis Is Inhibited by Bromophenacyl Bromide

, 1985
Frances M. Edinger, Arthur Penn
openalex   +1 more source

Nucleosome-free Region Dominates Histone Acetylation in Targeting SWR1 to Promoters for H2A.Z Replacement [PDF]

, 2013
Anand Ranjan, Gaku Mizuguchi, Peter Fitzgerald, Debbie Wei, Feng Wang, Yingzi Huang, Ed Luk, Christopher L. Woodcock, Carl Wu   +8 more
openalex   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Integrating TERT promoter mutations into risk stratification of papillary thyroid cancer. [PDF]

Endocr Connect
Yoo JH, Kim BR, Leem DE, Ryu HJ, Chi SA, Lee JH, Lee H, Kim HI, Chung YJ, Chung JH, Kim TH, Kim SW.   +11 more
europepmc   +1 more source

Genome-Wide Promoter Analysis of the SOX4 Transcriptional Network in Prostate Cancer Cells [PDF]

, 2009
Christopher D. Scharer, Colleen D. McCabe, Mohamed Ali‐Seyed, Michael F. Berger, Martha L. Bulyk, Carlos S. Moreno   +5 more
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Bidirectional promoters in Escherichia coli: regulatory rules and implications for gene expression noise. [PDF]

Nucleic Acids Res
Warman EA, Forrest D, Stringer AM, Wade JT, Grainger DC.   +4 more
europepmc   +1 more source

Promoters to Study Vascular Smooth Muscle [PDF]

, 2019
Raja Chakraborty, Fatima Zahra Saddouk, Ana Catarina Ribeiro Carrao, Diane S. Krause, Daniel M. Greif, Kathleen A. Martin   +5 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

High-throughput optimization of antibody production in CHO cells by tuning heavy- and light-chain promoter strength. [PDF]

Front Bioeng Biotechnol
Rahimi M, Adams AC, Grav LM, Nielsen LK, Lavado-García J.   +4 more
europepmc   +1 more source